Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivekimig in moderate to severe hidradenitis suppurativa – phase II dose-ranging, placebo-controlled trial
CTR20255064Phase 2Active
- Sponsor
- Sanofi
- Start
- Jan 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brivekimig in hidradenitis suppurativa (HS) (4 arms), sponsored by Sanofi. Primary endpoint: Proportion of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75). Started Jan 2026; status: active.
02
Drugs
brivekimig
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on CTR20255064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255064.